Arcellx Q3 2025 net loss widens to $55.8M; collaboration revenue drops 81%

Arcellx, Inc.

2025-Q3 EPS reported -$3.06 revenue$20,632,000

Cash, equivalents, and marketable securities of $576.0M as of Sep 30, 2025; expected to fund operations into 2028.
Collaboration revenue fell to $4.9M from $26.0M YoY, driven by completion of anito-cel dosing in iMMagine-1 trial.
R&D expenses decreased to $35.1M from $39.2M YoY; G&A expenses rose to $31.6M from $20.5M YoY on commercial readiness costs.
Net loss was $55.8M compared to $25.9M in Q3 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.